2 ГАУЗ СО «Свердловская областная клиническая больница №1», Екатеринбург, Россия
2. Manack A, Motsko SP, Haag-Molkenteller C et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 2011; 30: 395–401.
3. Sung BM, Oh DJ, Choi MH, Choi HM. Chronic kidney disease in neurogenic bladder. Nephrology (Carlton) 2018; 23 (3): 231–6.
4. Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995; 74: 415–8.
5. Metz LM, McGuinness SD, Harris C. Urinary tract infections may trigger relapse in multiple sclerosis. Axone 1998; 19: 67–70.
6. Böthig R, Fiebag K, Thietje R et al. Morbidity of urinary tract infection after urodynamic examination of hospitalized SCI patients: the impact of bladder management. Spinal Cord 2013; 51: 70–3.
7. Quek P, Tay LH. Morbidity and significant bacteriuria after urodynamic studies. Ann Acad Med Singapore 2004; 33: 754–7.
8. Almallah YZ, Rennie CD, Stone J et al. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology 2000; 56: 37–9.
9. Evans CT, Rogers TJ, Chin A et al. Antibiotic prescribing trends in the emergency department for veterans with spinal cord injury and disorder 2002–2007. J Spinal Cord Med 2013; 36: 492–8.
10. Togan T, Azap OK, Durukan E et al. The prevalence, etiologic agents and risk factors for urinary tract infection among spinal cord injury patients. Jundishapur J Microbiol 2014; 7: e8905.
11. Yoon SB, Lee BS, Lee KD et al. Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital. Spinal Cord 2014; 52: 298–301.
12. Martins CF, Bronzatto E, Neto JM et al. Urinary tract infection analysis in a spinal cord injured population undergoing rehabilitation – how to treat? Spinal Cord 2013; 51: 193–5.
13. Esclarín De Ruz A, García Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 2000; 164: 1285–9.
14. Goetz LL, Howard M, Cipher D et al. Occurrence of candiduria in a population of chronically catheterized patients with spinal cord injury. Spinal Cord 2010; 48: 51–4.
15. Flores-Mireles AL, Walker JN, Caparon M et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 13: 269–84.
16. Vasudeva P, Madersbacher H. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored. Neurourol Urodyn 2014; 33: 95–100.
17. Gamé X, Castel-Lacanal E, Bentaleb Y et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008; 53: 613–8.
18. Jia C, Liao LM, Chen G et al. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord 2013; 51: 487–90.
19. Neal DE. Host defense mechanisms in urinary tract infections. Urol Clin North Am 1999; 26:
20. Merritt JL. Residual urine volume: correlate of urinary tract infection in patients with spinal cord injury. Arch Phys Med Rehabil 1981; 62: 558–61.
21. Taylor TA, Waites KB. A quantitative study of genital skin flora in male spinal cord-injured outpatients. Am J Phys Med Rehabil 1993; 72: 117–21.
22. Waites KB, Canupp KC, DeVivo MJ. Microbiology of the urethra and perineum and its relationship to bacteriuria in community-residing men with spinal cord injury. J Spinal Cord Med 2004; 27: 448–52.
23. Parsons CL, Greenspan C, Moore SW et al. Role of surface mucin in primary antibacterial defense of bladder. Urology 1977; 9: 48–52.
24. Parsons CL, Shrom SH, Hanno PM et al. Bladder surface mucin. Examination of possible mechanisms for its antibacterial effect. Invest Urol 1978; 16: 196–200.
25. Vaidyanathan S, McDicken IW, Soni BM et al. Secretory immunoglobulin A in the vesical urothelium of patients with neuropathic bladder – an immunohistochemical study. Spinal Cord 2000; 38: 378–81.
26. Schlager TA, Grady R, Mills SE et al. Bladder epithelium is abnormal in patients with neurogenic bladder due to myelomeningocele. Spinal Cord 2004; 42: 163–8.
27. Vaidyanathan S, McDicken IW, Ikin AJ et al. A study of cytokeratin 20 immunostaining in the urothelium of neuropathic bladder of patients with spinal cord injury. BMC Urol 2002; 2: 7.
28. Balsara ZR, Ross SS, Dolber PC et al. Enhanced Susceptibility to Urinary Tract Infection in the Spinal Cord-Injured Host with Neurogenic Bladder. Infect Immun 2013; 81: 3018–26.
29. Chaudhry R, Madden-Fuentes RJ, Ortiz TK et al. Inflammatory response to Escherichia coli urinary tract infection in the neurogenic bladder of the spinal cord injured host. J Urol 2014; 191: 1454–61.
30. Iversen PO, Hjeltnes N, Holm B et al. Depressed immunity and impaired proliferation of hematopoietic progenitor cells in patients with complete spinal cord injury. Blood 2000; 96: 2081–3.
32. Garibaldi RA, Burke JP, Dickman ML et al. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med 1974; 291: 215–9.
33. Hartstein AI, Garber SB, Ward TT et al. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control 1981; 2: 380–6.
34. Nickel JC, Grant SK, Costerton JW. Catheter-associated bacteriuria. An experimental study. Urology 1985; 26: 369–75.
35. Hooton TM, Bradley SF, Cardenas DD et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 625–63.
36. Su RR, Palta M, Lim A, Wald ER. Pyuria as a Marker of Urinary Tract Infection in Neurogenic Bladder: Is It Reliable? Pediatr Infect Dis J 2019.
37. Pannek J, Wöllner J. Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions. Res Rep Urol 2017; 9: 121–7.
38. Goetz LL, Cardenas DD, Kennelly M et al. International Spinal Cord Injury Urinary Tract Infection Basic Data Set. Spinal Cord 2013; 51: 700–4.
39. Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol 2012; 187: 391–7.
40. Darouiche RO, Al Mohajer M, Siddiq DM et al. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil 2014; 95: 290–6.
41. Dow G, Rao P, Harding G et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis 2004; 39: 658–64.
42. Memikoğlu KO, Bayar B, Kurt O, Cokça F. In vitro sensitivity of methicillin-resistant Staphylococcus aureus to fusidic acid and trimethoprim-sulfamethoxazole. Mikrobiyol Bul 2002; 36: 141–5.
43. Grim SA, Rapp RP, Martin CA et al. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25: 253–64.
44. Paul M, Bishara J, Yahav D et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015; 350: h2219.
45. Kahan FM, Kahan JS, Cassidy PJ et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364–86.
46. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15: e732-9.
47. Cai Y, Fan Y, Wang R et al. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother 2009; 64: 563–6.
48. Rodríguez-Martínez JM, Ballesta S, Pascual A. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents 2007; 30: 366–8.
49. Falagas ME, Kastoris AC, Karageorgopoulos DE et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and and clinical studies. Int J Antimicrob Agents 2009; 34: 111–20.
50. Mitsui T, Minami K, Morita H et al. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol 2000; 38: 434–8.
51. Sheriff MK, Foley S, McFarlane J et al. Long-term suprapubic catheterisation: clinical outcome and satisfaction survey. Spinal Cord 1998; 36: 171–6.
52. Shen L, Zheng X, Zhang C et al. Influence of different urination methods on the urinary systems of patients with spinal cord injury. J Int Med Res 2012; 40: 1949–57.
53. Guttmann L et al. The value of intermittent catheterisation in the early management of traumatic paraplegia and tetraplegia. Paraplegia 1966; 4: 63.
54. Wyndaele JJ. Intermittent catheterization: which is the optimal technique? Spinal Cord 2002; 40: 432.
55. Prieto-Fingerhut T et al. A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. Rehabil Nurs 1997; 22: 299.
56. Lapides, J et al. Clean, intermittent self-catheterization in the treatment of urinary tract disease.
J Urol 1972; 107: 458.
57. Kiddoo D et al. Randomized Crossover Trial of Single Use Hydrophilic Coated vs Multiple Use Polyvinylchloride Catheters for Intermittent Catheterization to Determine Incidence of Urinary Infection. J Urol 2015; 194: 174.
58. Bermingham SL, Hodgkinson S, Wright S et al. Pellowe Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. BMJ 2013; 346: e8639.
59. Woodbury MG et al. Intermittent catheterization practices following spinal cord injury: a national survey. Can J Urol 2008; 15: 4065.
60. Warren JW, Platt R, Thomas RJ et al. Antibiotic irrigation and catheter-associated urinary-tract infections. N Engl J Med 1978; 299: 570–3.
61. Davies AJ, Desai HN, Turton S et al. Does instillation of chlorhexidine into the bladder of catheterized geriatric patients help reduce bacteriuria? J Hosp Infect 1987; 9: 72–5.
62. Dudley MN, Barriere SL. Antimicrobial irrigations in the prevention and treatment of catheter-related urinary tract infections. Am J Hosp Pharm 1981; 38: 59–65.
63. Reiche T, Lisby G, Jørgensen S et al. A prospective, controlled, randomized study of the effect of a slow-release silver device on the frequency of urinary tract infection in newly catheterized patients. BJU Int 2000; 85: 54–9.
64. Thompson RL, Haley CE, Searcy MA et al. Catheter-associated bacteriuria. Failure to reduce attack rates using periodic instillations of a disinfectant into urinary drainage systems. JAMA 1984; 251: 747–51.
65. Gillespie WA, Simpson RA, Jones JE et al. Does the addition of disinfectant to urine drainage bags prevent infection in catheterised patients? Lancet 1983; 1: 1037–9.
66. Sweet DE, Goodpasture HC, Holi K et al. Evaluation of H2O2 prophylaxis of bacteriuria in patients with long-term indwelling Foley catheters: a randomized controlled study. Infect Control 1985; 6: 263–6.
67. Classen DC, Larsen RA, Burke JP et al. Prevention of catheter-associated bacteriuria: clinical trial of methods to block three known pathways of infection. Am J Infect Control 1991; 19: 136–42.
68. Saint S, Chenoweth CE. Biofilms and catheter-associated urinary tract infections. Infect Dis Clin North Am 2003; 17: 411–32.
69. Tenney JH, Warren JW. Bacteriuria in women with long-term catheters: paired comparison of indwelling and replacement catheters. J Infect Dis 1988; 157: 199–202.
70. Grahn D, Norman DC, White ML et al. Validity of urinary catheter specimen for diagnosis of urinary tract infection in the elderly. Arch Intern Med 1985; 145: 1858–60.
71. Salameh A, Mohajer Al M, Darouiche RO. Prevention of urinary tract infections in patients with spinal cord injury. CMAJ 2015; 187: 807–11.
72. D’Hondt F, Everaert K. Urinary tract infections in patients with spinal cord injuries. Curr Infect Dis Rep 2011; 13: 544–51.
73. Morton SC, Shekelle PG, Adams JL et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002; 83: 129–38.
74. Hess MJ, Hess PE, Sullivan MR et al. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008;
75. Opperman EA. Cranberry is not effective for the prevention or treatment of urinary tract infections in individuals with spinal cord injury. Spinal Cord 2010; 48: 451–6.
76. Phé V, Pakzad M, Haslam C et al. Open label feasibility study evaluating d-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn. Epub 2016 Nov 4.
77. Hachen HJ. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol 1990; 143 (4): 759–62.
78. Darouiche RO, Green BG, Donovan WH et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology 2011; 78: 341–6.
79. Sybesma W, Zbinden R, Chanishvili N et al. Bacteriophages as potential treatment for urinary tract infections. Front Microbiol 2016; 7: 465.
80. Emmanuel A, Kumar G, Christensen P et al. Long-term costeffectiveness of transanal irrigation in patients with neurogenic bowel dysfunction. PLoS One 2016; 11 (8): e0159394.
81. Cox L, He C, Bevins J et al. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can Urol Assoc J 2017;
11 (9): E350–E354.
82. Huen KH, Nik-Ahd F, Chen L et al. Neomycin-polymyxin or gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on clean intermittent catheterization. J Pediatr Urol 2019; 15 (2): 178.e1–178.e7.
83. Cruz F, Nitti V. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourol Urodyn 2014; 33 (Suppl. 3): S26–31.
84. Martens FM, den Hollander PP, Snoek GJ et al. Quality of life in complete spinal cord injury patients with a Brindley bladder stimulator compared to a matched control group. Neurourol Urodyn 2011; 30: 551–5.
85. Sievert KD, Amend B, Gakis G et al. Quality of life in complete spinal cord injury patients with a Brindley bladder stimulator compared to a matched control group. Ann Neurol 2010; 67: 74–84.
Для цитирования:Филиппова Е.С., Баженов И.В., Зырянов А.В., Борзунов И.В. Инфекции мочевыводящих путей у больных нейрогенным мочевым пузырем. Consilium Medicum. 2019; 21 (12): 139–144. DOI: 10.26442/20751753.2019.12.190676Учредитель: ЗАО «Медицинские издания»
Издатель: ЗАО "Консилиум Медикум"
Свидетельство о регистрации СМИ ЭЛ №ФС77-69134 от 24 марта 2017 г.